HB0036 vs HLX301

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-L1 / TIGIT · full Non-Small Cell Lung Cancer pipeline

HB0036

Developed by Shanghai Huaota Biopharmaceutical Co.

Phase 1/2 in Non-Small Cell Lung Cancerbispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

HLX301

Developed by Shanghai Henlius Biotech

Phase 1/2 in Non-Small Cell Lung Cancerbispecific antibody
Weak signal

NCT05102214 · Phase 1/2 · status unknown

Patients were assigned to dose-escalation and expansion cohorts without randomization or blinding and without a control arm, so this cannot show whether HLX301 outperforms an alternative treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Phase 1a: Safety assessments in patients receiving the trial drug (2 years); Phase 1a: The proportion of patients experiencing dose limiting toxicity (DLT) events (From baseline to the end of cycle 2 (28 days)); Phase 1a: The maximum tolerated dose (MTD) of HLX301 (From baseline to the end of cycle 2 (28 days)); Phase 1b: Recommended phase 2 dose (RP2D) (From baseline to 48 weeks after first infusion); Phase 2: Objective response rate (ORR) defined as achieving a complete response or partial response as determined by the investigator according to RECIST v1.1 (2 years); Phase 2: Disease control rate (DCR) defined as achieving the complete response, partial response, or stable disease as determined by the investigator according to RECIST v1.1 (2 years); Phase 2: Duration of response (DOR) defined as the time from the first occurrence of a documented ORR to disease progression, as determined by the investigator according to RECIST v1.1 (2 years): Interim phase 1a dose-escalation data (data cut-off Oct 27, 2023; 9 patients enrolled): 1 patient (11.1%) in the 5.0 mg/kg cohort reported a treatment-related dose-limiting toxicity (grade 3 cytokine release syndrome), and the maximum tolerable dose in this phase 1a was not determined. HLX301 showed an acceptable safety profile with preliminary anti-tumor activity.

Result source: NCT05102214

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHB0036HLX301
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

HB0036
—Not reported
HLX301
—Not reported

OS, median

HB0036
—Not reported
HLX301
—Not reported

ORR

HB0036
—Not reported
HLX301
—Not reported

Duration of response, median

HB0036
—Not reported
HLX301
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HB0036: no structured comparison results are available for Non-Small Cell Lung Cancer.

HLX301: no structured comparison results are available for Non-Small Cell Lung Cancer.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HB0036's landscape · HLX301's landscape